EyeGate pharma

Committed to Developing Patient-Friendly Treatments and Therapeutics for Ocular Diseases

CORPORATE FACTSHEET

AT A GLANCE

EyeGate Pharma is dedicated to developing therapeutics for treating ocular disorders.

The EyeGate II® Delivery System (EGDS):

- is a unique non-invasive ocular delivery system, which delivers a wide array of molecules, including biologics and nanoparticles,
- is designed to overcome the shortcomings of current dosing approaches by delivering substantially more drug more quickly, and
- over 1,700 treatments have been performed that eliminates the need for self-administered eye drops.

EyeGate is focusing its efforts on developing a reformulated coricosteroid, EGP-437 that eliminates the need for self-administered eye drops.

Recently completed a randomized, double-masked Phase III clinical trial in patients with anterior uveitis.

Treatments can be performed by a variety of eye-care providers.

EyeGate Pharma is headquartered in Waltham, Massachusetts.

OVERVIEW AND STRATEGY

Eyegate Pharmaceuticals, Inc., is a privately held specialty pharmaceutical company that is developing proprietary drug formulations designed to address two major issues in ophthalmic medicine: patient compliance and safety. The formulations utilize an innovative non-invasive drug delivery platform which is highly effective and has an excellent safety profile.

The EyeGate® II Delivery System (EGDS) which features a compact, elegant, and easy-to-use device, delivers EGP-437 (and other specially formulated drugs) non-invasively and quickly into the ocular tissues, which can accelerate onset of action, dramatically reduce treatment frequency (vs. eye drops) and sustain therapeutic effect. Treatment takes only a few minutes.

TECHNOLOGY

NON-INVASIVE DRUG DELIVERY



EyeGate Pharma's transscleral iontophoresis delivery platform, the EGDS, was originally designed at the Bascom Palmer Eye Institute at the University of Miami and optimized by EyeGate Pharma.

The EyeGate® II Delivery System consists of two parts: a reusable battery-powered generator and a disposable applicator that contains the drug. The EGDS utilizes a low voltage electrical current to safely and effectively deliver optimal quantities of drugs to the anterior or posterior segments of the eye. It is capable of delivering a wide range of therapeutics (e.g., low molecular weight compounds, biologics) through its ocular applicator.

Over 1700 treatments have been safely performed. EyeGate is the first company to complete clinical trials using iontophoresis technology to deliver an active compound (EGP-437) into the eye under an investigational new drug (IND) protocol.

THE EYEGATE® II ADVANTAGES

- Non-invasive, needle-free drug delivery to anterior and posterior segments of the eye
- Delivers substantially more drug to ocular tissues than topical approaches
- Compatible with a wide variety of therapeutics (low-molecular weight compounds, biologics)
- Eliminates patient compliance issues
- Excellent safety profile

MANAGEMENT TEAM

Stephen From, President and Chief Executive Officer
Michael A. Patane, PhD, Chief Scientific Officer
Michael P. Manzo, Vice President, Engineering
Paul Perkins, Senior Director, Finance and Human Resources
Carol Assang, Dir. Clinical Operations
Lisa Brandano, Dir. Clinical Operations

BOARD OF DIRECTORS

Paul Chaney
Morton Goldberg, MD*
Praveen Tyle, PhD
Thomas Balland
Thomas E. Hancock
Bernard Malfroy-Camine
Stephen From

* Participation by Board Member does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System

SCIENTIFIC ADVISORY BOARD

C. Stephen Foster, MD
Richard H. Guy, PhD
Jean-Marie Parel, PhD
Michael Raizman, MD
Sanjay Rao, MD
Eric Souied, MD, PhD

CONTACT INFORMATION

Stephen From
President and CEO
EyeGate Pharma
271 Waverley Oaks Road
Suite108
Waltham, MA 02452
781.788.8869
sdfrom@eyegatepharma.com

CLINICAL TRIALS PROGRAM

Our approach to treating ocular disorders is to overcome the shortcomings of current dosing approaches by dosing substantially more drug quickly via the EyeGate® II Delivery System.

EGP-437 *(Dexamethasone Phosphate)*	Phase III	Anterior Uveitis	Completed**
	Phase III (ALLUVION)	Dry Eye Syndrome	Completed
	Phase II	Dry Eye Syndrome	Completed
	Phase I / II	Anterior Uveitis	Completed
	Phase I	Anterior Scleritis	Initiated
Eyegate® II Delivery System	Phase I	Healthy Volunteer	Completed

****RESULTS:** EGP-437 matches the standard-of-care response rate in patients with anterior uveiits. Two ionotophoretic treatments of EGP-437 achieved the same response rate as the current standard of care prednisolone acetate 1% ophthalmic suspension administered as daily eyedrops.

MARKET OPPORTUNITY

In 2009, the total market for ocular diseases was estimated at over $15 billion, and is expected to grow to $33 billion by 2023. There is a clear need for alternative drug delivery systems to treat ocular diseases. EyeGate Pharma is targeting a 2015 launch for EGP-437.

EyeGate Pharma is developing an internal pipeline of products, including its lead candidate (EGP-437) for inflammatory conditions. The Company is pursuing partnerships with pharmaceutical and biotechnology companies that are marketing or developing products for serious ocular conditions such as age-related macular degeneration and diabetic retinopathy.

MILESTONES

2013	• EGP-437 matches standard-of-care's response rate in Ph III study in patients with Anterior Uveitis
2012	• Initiates Ph I study of EGP-437 in pateints with non-necrotizing anterior scleritis • Initiates Ph III trial of EGP-437 in patients with anterior uveitis
2011	• Completed Ph III pivotal trial in dry eye (ALLUVION) • Secures additional $5.9M series D funding
2010	• Secured additional $6M Series D venture financing • Initiated Ph III pivotal trial in dry eye (ALLUVION) • Completed End of Ph II meeting with the FDA
2009	• Raised $23M Series D venture financing • Completed three clinical trials: two safety/efficacy (dry eye, anterior uveitis) and one safety • Received Orphan Drug Designation from FDA and EMA for EGP-437 for treating corneal graft rejection
2008	• Raised $15M in Series C venture financing • Opened first-ever IND for ocular iontophoresis for EGP-437
2007	• Raised $12M Series B venture financing • Established US operations; built out management and R&D teams